EGA
ANIP icon

Eagle Global Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Eagle Global Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,560
Closed -$407K – 370
2015
Q2 		$407K Hold
6,560
– – 0.01% 246
2015
Q1 		$410K Buy
6,560
+2,390
+57% +$145K 0.01% 218
2014
Q4 		$235K Buy
+4,170
New +$184K 0.01% 287

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Eagle Global Advisors's ANIP Position: Q3 2015 in Review

Eagle Global Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2015, closing a stake of 6,560 shares — an estimated $407K sold.

Eagle Global Advisors first reported a position in ANIP in Q4 2014 and held it in 3 quarters. The position peaked at $410K in Q1 2015. 121 funds tracked by Wall St. Rank hold ANIP as of Q3 2015.

  • Eagle Global Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Eagle Global Advisors sold 6,560 ANI Pharmaceuticals shares in Q3 2015, an estimated $407K.
  • Eagle Global Advisors first reported a position in ANI Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Eagle Global Advisors's ANI Pharmaceuticals position peaked at $410K in Q1 2015.
  • 121 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2015.

Based on Eagle Global Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.